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a  b  s  t  r  a  c  t
Salmonella  enterica  serovars  Typhi  and  Paratyphi  (S. Paratyphi)  A  and  B cause  enteric  fever  in  humans.
Of  the  paratyphoid  group,  S. Paratyphi  A is the  most  common  serovar.  In  2000, there  were  an  estimated
5.4  million  cases  of S.  Paratyphi  A worldwide.  More  recently  paratyphoid  fever  has  accounted  for  an
increasing  fraction  of  all cases  of enteric  fever.  Although  vaccines  for typhoid  fever have been  developed
and  in  use  for  decades,  vaccines  for paratyphoid  fever  have  not  yet  been  licensed.  Several  S. Paratyphi  A
vaccines,  however,  are  in development  and  based  on  either  whole  cell  live-attenuated  strains  or  repeating
units of  the  lipopolysaccharide  O-antigen  (O:2)  conjugated  to different  protein  carriers.  An O-speciﬁc
polysaccharide  (O:2)  of  S. Paratyphi  A conjugated  to tetanus  toxoid  (O:2-TT),  for  example,  has  been
determined  to be  safe  and  immunogenic  after one  dose  in  Phase  I and  Phase  II trials.  Two  other  conjugated
vaccine  candidates  linked  to  diphtheria  toxin  and  a live-attenuated  oral  vaccine  candidate  are  currently  in
preclinical  development.  As promising  vaccine  candidates  are  advanced  along  the  development  pipeline,
an  adequate  supply  of vaccines  will  need  to  be ensured  to meet growing  demand,  particularly  in the  most
affected  countries.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).
Salmonella bacteria, of the Enterobacteriaceae family, comprise
a group of Gram-negative, non-spore-forming, facultative anaer-
obic bacilli [1]. Collectively, these bacteria are responsible for
a broad-spectrum of gastrointestinal and systemic illnesses that
include but are not limited to enteric fever, food-borne diarrheal
illness and invasive nontyphoidal Salmonella disease. Salmonella
enterica serovar Typhi (S. Typhi) and Salmonella enterica serovar
Paratyphi (S. Paratyphi) A and B cause enteric fever, a febrile illness
exclusively in humans. Of the paratyphoid group, S. Paratyphi A is
the most common serovar. The remaining Salmonella bacteria are
mostly zoonotic nontyphoidal serotypes that tend to infect a variety
of hosts [2]. In 2000, there were an estimated 5.4 million cases of S.
Paratyphi A worldwide [3], with highest burdens on the Indian sub-
continent and South East Asia. Unlike NTS and S. Typhi, there does
not seem to be such high burden of paratyphoid in sub-Saharan
Africa.
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Studies from South Asia have reported an increased number
of paratyphoid fever cases, but the same has not been true in
other regions. For example, there is a high prevalence of S. Typhi
in urban areas of Kenya, Malawi, Tanzania and the Democratic
Republic of Congo but virtually no reports of S. Paratyphi [4,5].
Low prevalence, however, does not translate into low risk. Severe
complications from S. Paratyphi infection mirror those of S. Typhi,
including hypotensive shock, small bowel perforation, bradycardia,
meningitis, osteomyelitis and multi-organ abscesses [6]. Chronic
carriage and long-term bacterial shedding, well characterized for
S. Typhi, has also been described for S. Paratyphi A [7]. Because
patients with S. Paratyphi A generally present with non-speciﬁc
febrile illness, diagnosis is dependent on laboratory conﬁrmation.
However, there is a relative lack of reliable diagnostics for enteric
fever, so most cases are treated without isolating or serotyping the
infecting organism. The gold standard for diagnosis remains bone-
marrow culture (80–95% sensitive). However, this is rarely used
and is instead substituted with blood culture in areas where it is
available. Stool culture can also be utilized as a means for case
identiﬁcation but may  require a logistically challenging collection
of multiple samples to increase sensitivity.
http://dx.doi.org/10.1016/j.vaccine.2016.03.106
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The lack of a clinically relevant animal model has made it difﬁ-
cult to develop improved diagnostics. However, a number of new
diagnostic technologies are being developed de novo or adapted
from other ﬁelds. For example, researchers at the International
Centre for Diarrheal Disease Research, Bangladesh recently devel-
oped the TPTest which detects Salmonella-speciﬁc IgA responses
in lymphocyte culture supernatant [8]. Results of the TPTest can
be used to distinguish enteric fever infection; it cannot, however,
differentiate between S. Typhi and S. Paratyphi A. Furthermore,
the time to identiﬁcation is not signiﬁcantly faster than blood cul-
ture. Molecular methodologies such as quantitative real-time PCR,
DNA ﬁngerprinting, pulse-ﬁeld electrophoresis and, more recently,
whole-genome sequencing are also being used to differentiate
and quantify bacterial strains in clinical samples. The sensitivity
and speciﬁcity of these diagnostics are inﬂuenced by multiple fac-
tors, including antimicrobial use, bacterial burden in the peripheral
blood, the timing of blood collection and the volume of blood col-
lected, particularly for children under the age of ﬁve years. Despite
their potential, these leading-edge technologies may  not be avail-
able in most resource-constrained laboratories for some time.
The strategies and challenges of preventing and treating paraty-
phoid are similar to those for typhoid. The treatment of S. Paratyphi
has been complicated in recent years by the emergence of antimi-
crobial resistance, speciﬁcally to ﬂuoroquinolones and naladixic
acid [9,10]. There is evidence that S. Paratyphi A has a greater
tendency toward resistance than S. Typhi. Furthermore, when treat-
ment is given, it can often be delayed due to the non-speciﬁc
nature of clinical symptoms and the lack of a reliable test for either
infection or drug resistance. Because paratyphoid is spread by the
fecal-oral route, provision of safe drinking water and uncontam-
inated food coupled with implementation of standard hygienic
practices can signiﬁcantly reduce transmission in endemic sett-
ings. As S. Paratyphi A is primarily transmitted outside of the
home [11], case identiﬁcation and treatment of travelers can be
effective in preventing outbreaks [12]. While the most effective
means of controlling S. Paratyphi is through the availability of clean
water supplies and working sanitation services, these infrastruc-
tural changes tend to occur slowly. Given the complexities and
limitations of other interventions, the development of a safe and
effective vaccine remains a priority for controlling the spread of
paratyphoid disease.
1. Biological feasibility and general approaches for
paratyphoid vaccine development for low- and
middle-income markets
Vaccines for S. Paratyphi are currently not available. However,
microbiological similarities between serovar S. Typhi and S. Paraty-
phi A and the fact that there are licensed, available vaccines for
S. Typhi support the biological feasibility for S. Paratyphi vaccine
development. A killed, whole-cell parenteral TAB (Typhi/Paratyphi
A/Paratyphi B) vaccine was used for several decades and consisted
of killed strains of 1000 million S. Typhi, 750 million S. Paratyphi
A, and 750 million S. Paratyphi B cells that provided some level of
protective immunity against infection. Although this vaccine is no
longer administered on account of its relatively severe side effects,
the development of the vaccine attests to the possibility of vaccine-
induced protection against S. Paratyphi [13]. S. Paratyphi A vaccines
currently in development are primarily based on whole-cell live-
attenuated strains and repeating units of the lipopolysaccharide
O-antigen, (O:2) conjugated to a range of protein carriers. Recently,
vaccination with the oral, live-attenuated S. Typhi vaccine, Ty21a
strain, has been shown to elicit a humoral immune response with
in vitro cross-reactivity against S. Paratyphi A and B [13]. Addi-
tional efforts are underway to develop subunit vaccines based on
the lipopolysaccharide antigen that has been previously described
as a virulence factor and a target of host immunity [14]. Regardless
of the type of vaccine developed, the co-endemicity of paratyphoid
A with typhoid fever in areas such as South and Southeast Asia, will
likely require a bivalent vaccine with a focus on infants and young
children.
2. Technical and regulatory assessment
In 2013, the World Health Organization published a guidance
document on the regulation and prequaliﬁcation of typhoid con-
jugate vaccines [15]. Although no such pathway has yet been
developed for paratyphoid vaccines, the typhoid vaccine frame-
work can serve as a surrogate until one is established. There is
currently no immune correlate of protection identiﬁed for S. Paraty-
phi A in humans as exists for anti-Vi and protection from S. Typhi
infection. There are, however, in vitro assays that quantify the
positive correlation between serum antibody levels and in vitro
bactericidal activity (SBA) induced by either natural infection or
immunization. Still, there is no well-established animal model for
S. Paratyphi A infection to evaluate pre-clinical efﬁcacy. To address
this deﬁciency in vaccine development, an experimental human
challenge model using S. Paratyphi A is being developed [16] to
evaluate clinical outcomes and immune response following natural
infection and vaccination.
3. Status of vaccine R&D activities
Several research groups and vaccine manufacturers are in the
process of developing monovalent S. Paratyphi A and bivalent S.
Paratyphi A/S. Typhi glycoconjugate vaccines (Table 1). The US
National Institutes of Health (NIH) has developed an O-speciﬁc
polysaccharide (O:2) conjugated to tetanus toxoid (O:2-TT) that
was found, in Phase 1 and 2 trials, to be both safe and immuno-
genic after one dose, although a booster antibody response was  not
evident after a second dose [17]. The NIH transferred the technol-
ogy to the Chengdu and Lanzhou Institutes of Biological Products in
China, the latter of which is currently conducting additional Phase
2 trials. The GSK Vaccines Institute for Global Health, with funds
from the Wellcome Trust, developed an S. Paratyphi A conjugate
using O:2 conjugated to CRM197, a nontoxic mutant of diphtheria
toxin (O:2-CRM197), intended to be combined in a bivalent formu-
lation with Vi-CRM197. This vaccine component has been shown
to be immunogenic with strong SBA against S. Paratyphi A when
delivered alone or in combination with Vi-CRM197. SBVGH trans-
ferred this technology to Biological E, Ltd. in India, which intends
to commercialize a bivalent vaccine—comprising Vi-CRM197 and
O:2-CRM197—that has activity against S. Typhi and S. Paratyphi
A[18]. The International Vaccine Institute has also conjugated the
O:2 of S. Paratyphi A to diphtheria toxoid (O:2-DT), though with an
adipic acid dihydrazide linker [19]. Clinical testing of this product
has not yet commenced. Finally, the Center for Vaccine Develop-
ment at the University of Maryland Baltimore (UMB) has developed
a live-attenuated, oral vaccine candidate for S. Paratyphi A (CVD
1902). The vaccine has two  independently attenuating mutations
in guaBA and clpX and has been shown to be safe and immunogenic
in preclinical studies [20]. A single dose of CVD 1902 was  also well
tolerated and immunogenic in Phase I trials. UMB  has licensed the
product to Bharat Biotech Ltd, Hyderabad, India, which will direct
future vaccine production and clinical research with guidance from
UMB. CVD 1902 is intended to ultimately become a part of a bivalent
vaccine, along with the live attenuated CVD 909 vaccine candidate
that targets S. Typhi.
2902 L.B. Martin et al. / Vaccine 34 (2016) 2900–2902
Table 1
Development status of current Salmonella Paratyphoid A vaccine candidates (POC = proof-of-concept trial).
Candidate name/identiﬁer Preclinical Phase I Phase II POC Phase III
O:2,12-TT + Vi-TT [NIH, Lanzhou] X
O:2,12-CRM197 + Vi-CRM197 [Biological E and SVGH] X
CVD 1902 + CVD 909 [UMB, Bharat Biotech] X
O:2,12-DT + Vi-DT [International Vaccine Institute] X
4. Likelihood for ﬁnancing
Though paratyphoid fever has garnered some attention from
global health funding agencies, commitment for vaccine develop-
ment, licensure and deployment requires sustained efforts. The
Strategic Advisory Group of Experts on Immunization, in 2011,
highlighted the need for developing a combined typhoid and
paratyphoid vaccine [21]. Despite these efforts, no concrete steps
by the GAVI Alliance have been taken for designating a priority
for vaccines against paratyphoid A, as was done for typhoid con-
jugate vaccines in 2008. The implementation of a Phase III clinical
trial to establish efﬁcacy the most promising S. Paratyphi A vac-
cine candidate will require funding from a variety of sources. With
the increasing burden of disease from S. Paratyphi A, and growing
attention to the identity of Salmonella enterica serovars responsible
for invasive Salmonella disease, control through vaccines appears to
become a signiﬁcant global health priority. Whether vaccines for
paratyphoid will be cost-effective as compared to other preven-
tive interventions, will require rigorous studies once paratyphoid
vaccines have shown to be efﬁcacious.
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